img

Global Pet Recombinant Vaccine Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pet Recombinant Vaccine Market Insights, Forecast to 2034

Vaccines prepared at the genetic level for pet vaccination are called pet recombinant vaccines.
The global Pet Recombinant Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Pet Recombinant Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Pet Recombinant Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Pet Recombinant Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Pet Recombinant Vaccine include Bayer Healthcare, Vetoquinol S.A, Boehringer Ingelheim, Ceva, Eli Lilly, Heska, Merck Animal Health, Merial (Sanofi) and Virbac, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Pet Recombinant Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Pet Recombinant Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Pet Recombinant Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pet Recombinant Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Pet Recombinant Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Pet Recombinant Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer Healthcare, Vetoquinol S.A, Boehringer Ingelheim, Ceva, Eli Lilly, Heska, Merck Animal Health, Merial (Sanofi) and Virbac, etc.



By Company


Bayer Healthcare
Vetoquinol S.A
Boehringer Ingelheim
Ceva
Eli Lilly
Heska
Merck Animal Health
Merial (Sanofi)
Virbac
Zoetis (Pfizer)
Segment by Type
Genetically Engineered Vaccines
Genetically Recombinant Vaccines
Transgenic Plant Vaccines
DNA Vaccines

Segment by Application


Dog
Cat
Dird
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Pet Recombinant Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Pet Recombinant Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pet Recombinant Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Pet Recombinant Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Pet Recombinant Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Genetically Engineered Vaccines
1.2.3 Genetically Recombinant Vaccines
1.2.4 Transgenic Plant Vaccines
1.2.5 DNA Vaccines
1.3 Market by Application
1.3.1 Global Pet Recombinant Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Dog
1.3.3 Cat
1.3.4 Dird
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pet Recombinant Vaccine Sales Estimates and Forecasts 2018-2034
2.2 Global Pet Recombinant Vaccine Revenue by Region
2.2.1 Global Pet Recombinant Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Pet Recombinant Vaccine Revenue by Region (2018-2024)
2.2.3 Global Pet Recombinant Vaccine Revenue by Region (2024-2034)
2.2.4 Global Pet Recombinant Vaccine Revenue Market Share by Region (2018-2034)
2.3 Global Pet Recombinant Vaccine Sales Estimates and Forecasts 2018-2034
2.4 Global Pet Recombinant Vaccine Sales by Region
2.4.1 Global Pet Recombinant Vaccine Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Pet Recombinant Vaccine Sales by Region (2018-2024)
2.4.3 Global Pet Recombinant Vaccine Sales by Region (2024-2034)
2.4.4 Global Pet Recombinant Vaccine Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Pet Recombinant Vaccine Sales by Manufacturers
3.1.1 Global Pet Recombinant Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global Pet Recombinant Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Pet Recombinant Vaccine in 2022
3.2 Global Pet Recombinant Vaccine Revenue by Manufacturers
3.2.1 Global Pet Recombinant Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Pet Recombinant Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pet Recombinant Vaccine Revenue in 2022
3.3 Global Key Players of Pet Recombinant Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Pet Recombinant Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pet Recombinant Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pet Recombinant Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pet Recombinant Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Pet Recombinant Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Pet Recombinant Vaccine Sales by Type
4.1.1 Global Pet Recombinant Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global Pet Recombinant Vaccine Forecasted Sales by Type (2024-2034)
4.1.3 Global Pet Recombinant Vaccine Sales Market Share by Type (2018-2034)
4.2 Global Pet Recombinant Vaccine Revenue by Type
4.2.1 Global Pet Recombinant Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Pet Recombinant Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pet Recombinant Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Pet Recombinant Vaccine Price by Type
4.3.1 Global Pet Recombinant Vaccine Price by Type (2018-2024)
4.3.2 Global Pet Recombinant Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pet Recombinant Vaccine Sales by Application
5.1.1 Global Pet Recombinant Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global Pet Recombinant Vaccine Forecasted Sales by Application (2024-2034)
5.1.3 Global Pet Recombinant Vaccine Sales Market Share by Application (2018-2034)
5.2 Global Pet Recombinant Vaccine Revenue by Application
5.2.1 Global Pet Recombinant Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Pet Recombinant Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pet Recombinant Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Pet Recombinant Vaccine Price by Application
5.3.1 Global Pet Recombinant Vaccine Price by Application (2018-2024)
5.3.2 Global Pet Recombinant Vaccine Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Pet Recombinant Vaccine Market Size by Type
6.1.1 US & Canada Pet Recombinant Vaccine Sales by Type (2018-2034)
6.1.2 US & Canada Pet Recombinant Vaccine Revenue by Type (2018-2034)
6.2 US & Canada Pet Recombinant Vaccine Market Size by Application
6.2.1 US & Canada Pet Recombinant Vaccine Sales by Application (2018-2034)
6.2.2 US & Canada Pet Recombinant Vaccine Revenue by Application (2018-2034)
6.3 US & Canada Pet Recombinant Vaccine Market Size by Country
6.3.1 US & Canada Pet Recombinant Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Pet Recombinant Vaccine Sales by Country (2018-2034)
6.3.3 US & Canada Pet Recombinant Vaccine Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Pet Recombinant Vaccine Market Size by Type
7.1.1 Europe Pet Recombinant Vaccine Sales by Type (2018-2034)
7.1.2 Europe Pet Recombinant Vaccine Revenue by Type (2018-2034)
7.2 Europe Pet Recombinant Vaccine Market Size by Application
7.2.1 Europe Pet Recombinant Vaccine Sales by Application (2018-2034)
7.2.2 Europe Pet Recombinant Vaccine Revenue by Application (2018-2034)
7.3 Europe Pet Recombinant Vaccine Market Size by Country
7.3.1 Europe Pet Recombinant Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Pet Recombinant Vaccine Sales by Country (2018-2034)
7.3.3 Europe Pet Recombinant Vaccine Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Pet Recombinant Vaccine Market Size
8.1.1 China Pet Recombinant Vaccine Sales (2018-2034)
8.1.2 China Pet Recombinant Vaccine Revenue (2018-2034)
8.2 China Pet Recombinant Vaccine Market Size by Application
8.2.1 China Pet Recombinant Vaccine Sales by Application (2018-2034)
8.2.2 China Pet Recombinant Vaccine Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Pet Recombinant Vaccine Market Size by Type
9.1.1 Asia Pet Recombinant Vaccine Sales by Type (2018-2034)
9.1.2 Asia Pet Recombinant Vaccine Revenue by Type (2018-2034)
9.2 Asia Pet Recombinant Vaccine Market Size by Application
9.2.1 Asia Pet Recombinant Vaccine Sales by Application (2018-2034)
9.2.2 Asia Pet Recombinant Vaccine Revenue by Application (2018-2034)
9.3 Asia Pet Recombinant Vaccine Sales by Region
9.3.1 Asia Pet Recombinant Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Pet Recombinant Vaccine Revenue by Region (2018-2034)
9.3.3 Asia Pet Recombinant Vaccine Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pet Recombinant Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Pet Recombinant Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bayer Healthcare
11.1.1 Bayer Healthcare Company Information
11.1.2 Bayer Healthcare Overview
11.1.3 Bayer Healthcare Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Bayer Healthcare Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer Healthcare Recent Developments
11.2 Vetoquinol S.A
11.2.1 Vetoquinol S.A Company Information
11.2.2 Vetoquinol S.A Overview
11.2.3 Vetoquinol S.A Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Vetoquinol S.A Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Vetoquinol S.A Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Information
11.3.2 Boehringer Ingelheim Overview
11.3.3 Boehringer Ingelheim Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Boehringer Ingelheim Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Boehringer Ingelheim Recent Developments
11.4 Ceva
11.4.1 Ceva Company Information
11.4.2 Ceva Overview
11.4.3 Ceva Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Ceva Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Ceva Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Company Information
11.5.2 Eli Lilly Overview
11.5.3 Eli Lilly Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Eli Lilly Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Eli Lilly Recent Developments
11.6 Heska
11.6.1 Heska Company Information
11.6.2 Heska Overview
11.6.3 Heska Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Heska Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Heska Recent Developments
11.7 Merck Animal Health
11.7.1 Merck Animal Health Company Information
11.7.2 Merck Animal Health Overview
11.7.3 Merck Animal Health Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Merck Animal Health Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Merck Animal Health Recent Developments
11.8 Merial (Sanofi)
11.8.1 Merial (Sanofi) Company Information
11.8.2 Merial (Sanofi) Overview
11.8.3 Merial (Sanofi) Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Merial (Sanofi) Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Merial (Sanofi) Recent Developments
11.9 Virbac
11.9.1 Virbac Company Information
11.9.2 Virbac Overview
11.9.3 Virbac Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Virbac Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Virbac Recent Developments
11.10 Zoetis (Pfizer)
11.10.1 Zoetis (Pfizer) Company Information
11.10.2 Zoetis (Pfizer) Overview
11.10.3 Zoetis (Pfizer) Pet Recombinant Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Zoetis (Pfizer) Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Zoetis (Pfizer) Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Pet Recombinant Vaccine Industry Chain Analysis
12.2 Pet Recombinant Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pet Recombinant Vaccine Production Mode & Process
12.4 Pet Recombinant Vaccine Sales and Marketing
12.4.1 Pet Recombinant Vaccine Sales Channels
12.4.2 Pet Recombinant Vaccine Distributors
12.5 Pet Recombinant Vaccine Customers
13 Market Dynamics
13.1 Pet Recombinant Vaccine Industry Trends
13.2 Pet Recombinant Vaccine Market Drivers
13.3 Pet Recombinant Vaccine Market Challenges
13.4 Pet Recombinant Vaccine Market Restraints
14 Key Findings in The Global Pet Recombinant Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pet Recombinant Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Genetically Engineered Vaccines
Table 3. Major Manufacturers of Genetically Recombinant Vaccines
Table 4. Major Manufacturers of Transgenic Plant Vaccines
Table 5. Major Manufacturers of DNA Vaccines
Table 6. Global Pet Recombinant Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Pet Recombinant Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Pet Recombinant Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Pet Recombinant Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Pet Recombinant Vaccine Revenue Market Share by Region (2018-2024)
Table 11. Global Pet Recombinant Vaccine Revenue Market Share by Region (2024-2034)
Table 12. Global Pet Recombinant Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 13. Global Pet Recombinant Vaccine Sales by Region (2018-2024) & (K Units)
Table 14. Global Pet Recombinant Vaccine Sales by Region (2024-2034) & (K Units)
Table 15. Global Pet Recombinant Vaccine Sales Market Share by Region (2018-2024)
Table 16. Global Pet Recombinant Vaccine Sales Market Share by Region (2024-2034)
Table 17. Global Pet Recombinant Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Pet Recombinant Vaccine Sales Share by Manufacturers (2018-2024)
Table 19. Global Pet Recombinant Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Pet Recombinant Vaccine Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Pet Recombinant Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Pet Recombinant Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Pet Recombinant Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Pet Recombinant Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pet Recombinant Vaccine as of 2022)
Table 25. Global Key Manufacturers of Pet Recombinant Vaccine, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Pet Recombinant Vaccine, Product Offered and Application
Table 27. Global Key Manufacturers of Pet Recombinant Vaccine, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Pet Recombinant Vaccine Sales by Type (2018-2024) & (K Units)
Table 30. Global Pet Recombinant Vaccine Sales by Type (2024-2034) & (K Units)
Table 31. Global Pet Recombinant Vaccine Sales Share by Type (2018-2024)
Table 32. Global Pet Recombinant Vaccine Sales Share by Type (2024-2034)
Table 33. Global Pet Recombinant Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Pet Recombinant Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Pet Recombinant Vaccine Revenue Share by Type (2018-2024)
Table 36. Global Pet Recombinant Vaccine Revenue Share by Type (2024-2034)
Table 37. Pet Recombinant Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Pet Recombinant Vaccine Price Forecast by Type (2024-2034) & (US$/Unit)
Table 39. Global Pet Recombinant Vaccine Sales by Application (2018-2024) & (K Units)
Table 40. Global Pet Recombinant Vaccine Sales by Application (2024-2034) & (K Units)
Table 41. Global Pet Recombinant Vaccine Sales Share by Application (2018-2024)
Table 42. Global Pet Recombinant Vaccine Sales Share by Application (2024-2034)
Table 43. Global Pet Recombinant Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Pet Recombinant Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Pet Recombinant Vaccine Revenue Share by Application (2018-2024)
Table 46. Global Pet Recombinant Vaccine Revenue Share by Application (2024-2034)
Table 47. Pet Recombinant Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Pet Recombinant Vaccine Price Forecast by Application (2024-2034) & (US$/Unit)
Table 49. US & Canada Pet Recombinant Vaccine Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Pet Recombinant Vaccine Sales by Type (2024-2034) & (K Units)
Table 51. US & Canada Pet Recombinant Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Pet Recombinant Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 53. US & Canada Pet Recombinant Vaccine Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Pet Recombinant Vaccine Sales by Application (2024-2034) & (K Units)
Table 55. US & Canada Pet Recombinant Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Pet Recombinant Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 57. US & Canada Pet Recombinant Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. US & Canada Pet Recombinant Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Pet Recombinant Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 60. US & Canada Pet Recombinant Vaccine Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Pet Recombinant Vaccine Sales by Country (2024-2034) & (K Units)
Table 62. Europe Pet Recombinant Vaccine Sales by Type (2018-2024) & (K Units)
Table 63. Europe Pet Recombinant Vaccine Sales by Type (2024-2034) & (K Units)
Table 64. Europe Pet Recombinant Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Pet Recombinant Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 66. Europe Pet Recombinant Vaccine Sales by Application (2018-2024) & (K Units)
Table 67. Europe Pet Recombinant Vaccine Sales by Application (2024-2034) & (K Units)
Table 68. Europe Pet Recombinant Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Pet Recombinant Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 70. Europe Pet Recombinant Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 71. Europe Pet Recombinant Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Pet Recombinant Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 73. Europe Pet Recombinant Vaccine Sales by Country (2018-2024) & (K Units)
Table 74. Europe Pet Recombinant Vaccine Sales by Country (2024-2034) & (K Units)
Table 75. China Pet Recombinant Vaccine Sales by Type (2018-2024) & (K Units)
Table 76. China Pet Recombinant Vaccine Sales by Type (2024-2034) & (K Units)
Table 77. China Pet Recombinant Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Pet Recombinant Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 79. China Pet Recombinant Vaccine Sales by Application (2018-2024) & (K Units)
Table 80. China Pet Recombinant Vaccine Sales by Application (2024-2034) & (K Units)
Table 81. China Pet Recombinant Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Pet Recombinant Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 83. Asia Pet Recombinant Vaccine Sales by Type (2018-2024) & (K Units)
Table 84. Asia Pet Recombinant Vaccine Sales by Type (2024-2034) & (K Units)
Table 85. Asia Pet Recombinant Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Pet Recombinant Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 87. Asia Pet Recombinant Vaccine Sales by Application (2018-2024) & (K Units)
Table 88. Asia Pet Recombinant Vaccine Sales by Application (2024-2034) & (K Units)
Table 89. Asia Pet Recombinant Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Pet Recombinant Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 91. Asia Pet Recombinant Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 92. Asia Pet Recombinant Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Pet Recombinant Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 94. Asia Pet Recombinant Vaccine Sales by Region (2018-2024) & (K Units)
Table 95. Asia Pet Recombinant Vaccine Sales by Region (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Type (2024-2034) & (K Units)
Table 98. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 100. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Application (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 104. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 105. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 107. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales by Country (2024-2034) & (K Units)
Table 109. Bayer Healthcare Company Information
Table 110. Bayer Healthcare Description and Major Businesses
Table 111. Bayer Healthcare Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Bayer Healthcare Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Bayer Healthcare Recent Developments
Table 114. Vetoquinol S.A Company Information
Table 115. Vetoquinol S.A Description and Major Businesses
Table 116. Vetoquinol S.A Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Vetoquinol S.A Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Vetoquinol S.A Recent Developments
Table 119. Boehringer Ingelheim Company Information
Table 120. Boehringer Ingelheim Description and Major Businesses
Table 121. Boehringer Ingelheim Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Boehringer Ingelheim Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Boehringer Ingelheim Recent Developments
Table 124. Ceva Company Information
Table 125. Ceva Description and Major Businesses
Table 126. Ceva Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Ceva Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Ceva Recent Developments
Table 129. Eli Lilly Company Information
Table 130. Eli Lilly Description and Major Businesses
Table 131. Eli Lilly Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. Eli Lilly Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Eli Lilly Recent Developments
Table 134. Heska Company Information
Table 135. Heska Description and Major Businesses
Table 136. Heska Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Heska Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Heska Recent Developments
Table 139. Merck Animal Health Company Information
Table 140. Merck Animal Health Description and Major Businesses
Table 141. Merck Animal Health Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Merck Animal Health Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Merck Animal Health Recent Developments
Table 144. Merial (Sanofi) Company Information
Table 145. Merial (Sanofi) Description and Major Businesses
Table 146. Merial (Sanofi) Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. Merial (Sanofi) Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Merial (Sanofi) Recent Developments
Table 149. Virbac Company Information
Table 150. Virbac Description and Major Businesses
Table 151. Virbac Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. Virbac Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Virbac Recent Developments
Table 154. Zoetis (Pfizer) Company Information
Table 155. Zoetis (Pfizer) Description and Major Businesses
Table 156. Zoetis (Pfizer) Pet Recombinant Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Zoetis (Pfizer) Pet Recombinant Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. Zoetis (Pfizer) Recent Developments
Table 159. Key Raw Materials Lists
Table 160. Raw Materials Key Suppliers Lists
Table 161. Pet Recombinant Vaccine Distributors List
Table 162. Pet Recombinant Vaccine Customers List
Table 163. Pet Recombinant Vaccine Market Trends
Table 164. Pet Recombinant Vaccine Market Drivers
Table 165. Pet Recombinant Vaccine Market Challenges
Table 166. Pet Recombinant Vaccine Market Restraints
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Pet Recombinant Vaccine Product Picture
Figure 2. Global Pet Recombinant Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pet Recombinant Vaccine Market Share by Type in 2022 & 2034
Figure 4. Genetically Engineered Vaccines Product Picture
Figure 5. Genetically Recombinant Vaccines Product Picture
Figure 6. Transgenic Plant Vaccines Product Picture
Figure 7. DNA Vaccines Product Picture
Figure 8. Global Pet Recombinant Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Pet Recombinant Vaccine Market Share by Application in 2022 & 2034
Figure 10. Dog
Figure 11. Cat
Figure 12. Dird
Figure 13. Others
Figure 14. Pet Recombinant Vaccine Report Years Considered
Figure 15. Global Pet Recombinant Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Pet Recombinant Vaccine Revenue 2018-2034 (US$ Million)
Figure 17. Global Pet Recombinant Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 18. Global Pet Recombinant Vaccine Revenue Market Share by Region (2018-2034)
Figure 19. Global Pet Recombinant Vaccine Sales 2018-2034 ((K Units)
Figure 20. Global Pet Recombinant Vaccine Sales Market Share by Region (2018-2034)
Figure 21. US & Canada Pet Recombinant Vaccine Sales YoY (2018-2034) & (K Units)
Figure 22. US & Canada Pet Recombinant Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Pet Recombinant Vaccine Sales YoY (2018-2034) & (K Units)
Figure 24. Europe Pet Recombinant Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Pet Recombinant Vaccine Sales YoY (2018-2034) & (K Units)
Figure 26. China Pet Recombinant Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Asia (excluding China) Pet Recombinant Vaccine Sales YoY (2018-2034) & (K Units)
Figure 28. Asia (excluding China) Pet Recombinant Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales YoY (2018-2034) & (K Units)
Figure 30. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Pet Recombinant Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 32. The Top 5 and 10 Largest Manufacturers of Pet Recombinant Vaccine in the World: Market Share by Pet Recombinant Vaccine Revenue in 2022
Figure 33. Global Pet Recombinant Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global Pet Recombinant Vaccine Sales Market Share by Type (2018-2034)
Figure 35. Global Pet Recombinant Vaccine Revenue Market Share by Type (2018-2034)
Figure 36. Global Pet Recombinant Vaccine Sales Market Share by Application (2018-2034)
Figure 37. Global Pet Recombinant Vaccine Revenue Market Share by Application (2018-2034)
Figure 38. US & Canada Pet Recombinant Vaccine Sales Market Share by Type (2018-2034)
Figure 39. US & Canada Pet Recombinant Vaccine Revenue Market Share by Type (2018-2034)
Figure 40. US & Canada Pet Recombinant Vaccine Sales Market Share by Application (2018-2034)
Figure 41. US & Canada Pet Recombinant Vaccine Revenue Market Share by Application (2018-2034)
Figure 42. US & Canada Pet Recombinant Vaccine Revenue Share by Country (2018-2034)
Figure 43. US & Canada Pet Recombinant Vaccine Sales Share by Country (2018-2034)
Figure 44. U.S. Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Pet Recombinant Vaccine Sales Market Share by Type (2018-2034)
Figure 47. Europe Pet Recombinant Vaccine Revenue Market Share by Type (2018-2034)
Figure 48. Europe Pet Recombinant Vaccine Sales Market Share by Application (2018-2034)
Figure 49. Europe Pet Recombinant Vaccine Revenue Market Share by Application (2018-2034)
Figure 50. Europe Pet Recombinant Vaccine Revenue Share by Country (2018-2034)
Figure 51. Europe Pet Recombinant Vaccine Sales Share by Country (2018-2034)
Figure 52. Germany Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 53. France Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 54. U.K. Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. Italy Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. Russia Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. China Pet Recombinant Vaccine Sales Market Share by Type (2018-2034)
Figure 58. China Pet Recombinant Vaccine Revenue Market Share by Type (2018-2034)
Figure 59. China Pet Recombinant Vaccine Sales Market Share by Application (2018-2034)
Figure 60. China Pet Recombinant Vaccine Revenue Market Share by Application (2018-2034)
Figure 61. Asia Pet Recombinant Vaccine Sales Market Share by Type (2018-2034)
Figure 62. Asia Pet Recombinant Vaccine Revenue Market Share by Type (2018-2034)
Figure 63. Asia Pet Recombinant Vaccine Sales Market Share by Application (2018-2034)
Figure 64. Asia Pet Recombinant Vaccine Revenue Market Share by Application (2018-2034)
Figure 65. Asia Pet Recombinant Vaccine Revenue Share by Region (2018-2034)
Figure 66. Asia Pet Recombinant Vaccine Sales Share by Region (2018-2034)
Figure 67. Japan Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 68. South Korea Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 69. China Taiwan Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 70. Southeast Asia Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 71. India Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 72. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales Market Share by Type (2018-2034)
Figure 73. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue Market Share by Type (2018-2034)
Figure 74. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales Market Share by Application (2018-2034)
Figure 75. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue Market Share by Application (2018-2034)
Figure 76. Middle East, Africa and Latin America Pet Recombinant Vaccine Revenue Share by Country (2018-2034)
Figure 77. Middle East, Africa and Latin America Pet Recombinant Vaccine Sales Share by Country (2018-2034)
Figure 78. Brazil Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 79. Mexico Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 80. Turkey Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 81. Israel Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 82. GCC Countries Pet Recombinant Vaccine Revenue (2018-2034) & (US$ Million)
Figure 83. Pet Recombinant Vaccine Value Chain
Figure 84. Pet Recombinant Vaccine Production Process
Figure 85. Channels of Distribution
Figure 86. Distributors Profiles
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed